Cornelis E.C.A. “Marcel” Hop is Vice-President at Genentech and supervising the DMPK department. He leads a team of about 85 scientists involved in acquisition and interpretation of ADME data in support of drug discovery and development ranging from early stage research to NDA and beyond. Before that, he was a Senior Director at Pfizer and a Senior Research Fellow at Merck and he received his Ph.D. from the University of Utrecht (The Netherlands). He has extensive experience in ADME sciences with a particular focus on PK optimization, human PK prediction, biotransformation, bioanalysis and the use of in silico approaches in drug discovery.
The future of drug development is likely to be deeply impacted by machine learning in a multitude of ways. This panel will reflect on the past, present, and future of what has made drug discovery flourish and fail; with a special focus on the technology driving cutting-edge precision medicine.